IGIoannis Gerasimou

Ioannis Gerasimou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ioannis Gerasimou has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Wearable-based sleep and activity tracking detects Parkinson's disease and associated pathological hallmarks

    by Apostolos Moustaklis, Ioannis Gerasimou, Charalampos Sotirakis, Paraskevi Chairta, Monica M. Kurtis, Natalia Del Campo, Tim Feige, Nils Schnalke, Maria-Luisa Almarcha Menargues, Kyriaki Michailidou, et al.

    Parkinson's disease (PD) is associated with sleep and motor function impairment, even in the early stages. Here, we investigated whether passive wearable-based sleep and activity tracking can detect PD and its associated pathological hallmarks, dopaminergic deficit and α-synuclein pathology. Sleep and activity metrics (SAM) were derived from free-living wrist accelerometry data of a U.S. cohort and used to train a machine learning model (SAM-PD) to distinguish persons with PD (n = 133) from healthy controls (n = 26). The model achieved an AUROC of 0.93 and an AUPRC of 0.98, demonstrated excellent test-retest reliability, and generalized without retraining to an independent European cohort (n = 40; 50% PwPD) monitored with a different device (AUROC, 0.95; AUPRC, 0.95). REM sleep duration, walking cadence, and low-level acceleration features were most predictive. Applied to a U.S. at-risk cohort, SAM-PD performed comparably to the resource-intensive Movement Disorder Society (MDS) prodromal PD risk score in detecting dopaminergic deficit (AUROC, 0.86 vs. 0.80; AUPRC, 0.45 vs. 0.46; n = 121; 12.4% prevalence) and α-synuclein pathology (AUROC, 0.76 for both; AUPRC 0.50 vs. 0.42; n = 114; 16.7% prevalence). A combination with the MDS score modestly improved detection. Findings support further evaluation of wearable monitoring for PD screening and biomarker enrichment in larger populations.

  • Open Access

    Clinical AI is Not (Yet) Trustworthy-But It Could Be

    by Ali Saad, Sofia B Dias, Ghada Alhussein, David Lyreskog, Ioannis Gerasimou, Beatriz Alves, Μaarten de Vos, Ioannis Drivas, John Zaras, Andreas Stergioulas, et al.

    The growing emphasis on trustworthy artificial intelligence (AI) in health care reflects a shift away from models optimized for predictive performance toward governable and auditable systems that can be adopted and sustained in clinical practice. Nonetheless, many clinical AI applications continue to privilege technical performance while underaddressing ethical, regulatory, and societal considerations, leading to concerns around robustness, transparency, and clinical adoption. To address this, governance frameworks such as the Assessment List for Trustworthy Artificial Intelligence (ALTAI) have been proposed to operationalize trust-related requirements across the AI lifecycle. However, evidence on the practical use of these frameworks remains limited. In this Viewpoint, we describe the application of ALTAI as a procedural governance framework within the Horizon Europe AI-PROGNOSIS project, which aims to support Parkinson disease diagnosis and care through predictive models and digital biomarkers derived from everyday devices. The seven ALTAI requirements (ie, human agency and oversight; technical robustness and safety; privacy and data governance; transparency; diversity, nondiscrimination, and fairness; societal and environmental well-being; and accountability) were mapped to key stages of the AI lifecycle within the project, including design and specification, data preparation, model development and validation, user interface and user experience deployment, external prospective validation, and overarching management and workflow. To examine how these requirements were perceived in practice, we conducted a structured internal survey among AI developers and data scientists involved in the AI-PROGNOSIS project (n=10). Participants rated the relevance of the 17 ALTAI subdomains using a three-point prioritization scale. Technical accuracy, data governance, and privacy were consistently rated as highly relevant, whereas societal impact received the lowest prioritization. This pattern reflects a documented tension in AI development, where technical teams tend to deprioritize broader societal concerns under delivery and performance constraints. Nonetheless, this work should be interpreted as a context-specific case study rather than a validation of ALTAI. The small sample size and project-specific setting limit generalizability, and these findings should not be considered as representative of broader clinical AI development. Overall, by making prioritization gaps explicit and embedding multidisciplinary review across lifecycle checkpoints, this case study illustrates how structured governance frameworks can surface implementation tensions and support accountable AI development. While these approaches do not resolve all of the aforementioned challenges, they provide practical guidance for integrating trust-related considerations into clinical AI projects.

  • Open Access

    Stakeholder Perspectives on Trustworthy AI for Parkinson Disease Management Using a Cocreation Approach: Qualitative Exploratory Study

    by Beatriz Alves, Ghada Alhussein, Sara Riggare, Therese Scott Duncan, Ali Saad, David M Lyreskog, Christos Chatzichristos, Ioannis Gerasimou, Stelios Hadjidimitriou, Leontios J Hadjileontiadis, et al.

    Background: Parkinson disease (PD) is the fastest-growing neurodegenerative disorder in the world, with prevalence expected to exceed 12 million by 2040, which poses significant health care and societal challenges. Artificial intelligence (AI) systems and wearable sensors hold potential for PD diagnosis, personalized symptom monitoring, and progression prediction. Nonetheless, ethical AI adoption requires several core principles, including user trust, transparency, fairness, and human oversight. Objective: This study aims to explore and synthesize the perspectives of diverse stakeholders, such as individuals living with PD, health care professionals, AI experts, and bioethicists. The aim was to guide the development of AI-driven digital health solutions, emphasizing transparency, data security, fairness, and bias mitigation while ensuring robust human oversight. These efforts are part of the broader Artificial Intelligence-Based Parkinson’s Disease Risk Assessment and Prognosis (AI-PROGNOSIS) European project, dedicated to advancing ethical and effective AI applications in PD diagnosis and management. Methods: An exploratory qualitative approach, based on 2 datasets constructed from cocreation workshops, engaged key stakeholders with diverse expertise to gather insights, ensuring a broad range of perspectives and enriching the thematic analysis. A total of 24 participants participated in the cocreation workshops, including 11 (46%) people with PD, 6 (25%) health care professionals, 3 (13%) AI technical experts, 1 (4%) bioethics expert, and 3 (13%) facilitators. Using a semistructured guide, key aspects of the discussion centered on trust, fairness, explainability, autonomy, and the psychological impact of AI in PD care. Results: Thematic analysis of the cocreation workshop transcripts identified 5 key main themes, each explored through various corresponding subthemes. AI trust and security (theme 1) was highlighted, focusing on data safety and the accuracy and reliability of the AI systems. AI transparency and education (theme 2) emphasized the need for educational initiatives and the importance of transparency and explainability of AI technologies. AI bias (theme 3) was identified as a critical theme, addressing issues of bias and fairness and ensuring equitable access to AI-driven health care solutions. Human oversight (theme 4) stressed the significance of AI-human collaboration and the essential role of human review in AI processes. Finally, AI’s psychological impact (theme 5) examined the emotional impact of AI on patients and how AI is perceived in the context of PD care. Conclusions: Our findings underline the importance of implementing robust security measures, developing transparent and explainable AI models, reinforcing bias mitigation and reduction strategies and equitable access to treatment, integrating human oversight, and considering the psychological impact of AI-assisted health care. These insights provide actionable guidance for developing trustworthy and effective AI-driven digital PD diagnosis and management solutions.


  • Open Access

    Stakeholder Perspectives on Trustworthy AI for Parkinson Disease Management Using a Cocreation Approach: Qualitative Exploratory Study (Preprint)

    by Beatriz Alves, Ghada Alhussein, Sara Riggare, Therese Scott Duncan, Ali Saad, David M Lyreskog, Christos Chatzichristos, Ioannis Gerasimou, Stelios Hadjidimitriou, Leontios J Hadjileontiadis, et al.

    BACKGROUND Parkinson disease (PD) is the fastest-growing neurodegenerative disorder in the world, with prevalence expected to exceed 12 million by 2040, which poses significant health care and societal challenges. Artificial intelligence (AI) systems and wearable sensors hold potential for PD diagnosis, personalized symptom monitoring, and progression prediction. Nonetheless, ethical AI adoption requires several core principles, including user trust, transparency, fairness, and human oversight. OBJECTIVE This study aims to explore and synthesize the perspectives of diverse stakeholders, such as individuals living with PD, health care professionals, AI experts, and bioethicists. The aim was to guide the development of AI-driven digital health solutions, emphasizing transparency, data security, fairness, and bias mitigation while ensuring robust human oversight. These efforts are part of the broader Artificial Intelligence-Based Parkinson’s Disease Risk Assessment and Prognosis (AI-PROGNOSIS) European project, dedicated to advancing ethical and effective AI applications in PD diagnosis and management. METHODS An exploratory qualitative approach, based on 2 datasets constructed from cocreation workshops, engaged key stakeholders with diverse expertise to gather insights, ensuring a broad range of perspectives and enriching the thematic analysis. A total of 24 participants participated in the cocreation workshops, including 11 (46%) people with PD, 6 (25%) health care professionals, 3 (13%) AI technical experts, 1 (4%) bioethics expert, and 3 (13%) facilitators. Using a semistructured guide, key aspects of the discussion centered on trust, fairness, explainability, autonomy, and the psychological impact of AI in PD care. RESULTS Thematic analysis of the cocreation workshop transcripts identified 5 key main themes, each explored through various corresponding subthemes. AI trust and security (theme 1) was highlighted, focusing on data safety and the accuracy and reliability of the AI systems. AI transparency and education (theme 2) emphasized the need for educational initiatives and the importance of transparency and explainability of AI technologies. AI bias (theme 3) was identified as a critical theme, addressing issues of bias and fairness and ensuring equitable access to AI-driven health care solutions. Human oversight (theme 4) stressed the significance of AI-human collaboration and the essential role of human review in AI processes. Finally, AI’s psychological impact (theme 5) examined the emotional impact of AI on patients and how AI is perceived in the context of PD care. CONCLUSIONS Our findings underline the importance of implementing robust security measures, developing transparent and explainable AI models, reinforcing bias mitigation and reduction strategies and equitable access to treatment, integrating human oversight, and considering the psychological impact of AI-assisted health care. These insights provide actionable guidance for developing trustworthy and effective AI-driven digital PD diagnosis and management solutions. CLINICALTRIAL